00:43 , Jan 24, 2017 |  BC Extra  |  Financial News

Aslan approved for Taipei listing

Aslan Pharmaceuticals Ltd. (Singapore) said it has been approved to list on Taiwan's Taipei Exchange. Founded in 2010, Aslan aims to acquire rights to molecules from pharmas, develop the candidates in Asia through proof-of-concept, and return...
07:00 , Sep 1, 2016 |  BC Extra  |  Company News

Aslan picks up preclinical A*STAR antibody

Aslan Pharmaceuticals Pte. Ltd. (Singapore) acquired worldwide rights from Singapore's Agency for Science, Technology and Research (A*STAR) to a preclinical antibody targeting macrophage stimulating 1 receptor c-Met-related tyrosine kinase ( MST1R; RON; CD136). A*STAR will...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Bristol-Myers, Aslan deal

Aslan said Bristol-Myers reacquired rights to develop and commercialize cancer compound ASLAN002 ( BMS-777607) in China, Australia, Korea, Taiwan and other Asian territories. Aslan is to receive $10 million up front and is eligible...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Lion's share of the work

Aslan Pharmaceuticals Pte. Ltd.'s 2011 deal with Bristol-Myers Squibb Co. (NYSE:BMY) was atypical in terms of stage and scope, but the biotech thinks the partnership validates its business model of in-licensing cancer compounds, doing development...
07:00 , Aug 10, 2016 |  BC Extra  |  Company News

BMS reacquires rights to ASLAN002 from Aslan

Aslan Pharmaceuticals Pte. Ltd. (Singapore) said Bristol-Myers Squibb Co. (NYSE:BMY) reacquired rights to develop and commercialize cancer compound ASLAN002 ( BMS-777607) in China, Australia, Korea, Taiwan and other Asian territories. Aslan is to receive $10...
01:31 , Jul 17, 2015 |  BC Extra  |  Company News

Aslan, NCCS to study GI cancers

Aslan Pharmaceuticals Pte. Ltd. (Singapore) and the National Cancer Centre Singapore signed a memorandum of understanding to jointly study gastrointestinal cancers that are disproportionately prevalent in Asia. Aslan and NCCS plan to study gastric cancer,...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

ASLAN002: Phase I data

An open-label, Australian Phase I trial in 39 patients with solid tumors showed that once-daily and twice-daily doses of oral ASLAN002 for a minimum of 28 days were well tolerated and led to long-term stable...
07:00 , May 30, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Macrophage stimulating 1 receptor c-Met-related tyrosine kinase (MST1R; RON; CD136); c-Met proto-oncogene...
07:00 , May 30, 2013 |  BC Innovations  |  Cover Story

RON's new role

A Utah team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumor immune response.1 The findings build a case for directed drug discovery efforts against the target, which has...
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

Almirall, Aslan deal

Almirall granted Aslan exclusive, worldwide rights to develop LAS186323, a dihydroorotate dehydrogenase (DHODH) inhibitor in Phase I testing for rheumatoid arthritis. Aslan will conduct and fund development through the end of Phase II...